Inhalation

INH0426

Issue link: https://www.e-digitaleditions.com/i/1544305

Contents of this Issue

Navigation

Page 45 of 47

44 April 2026 Inhalation overreacted to common allergens including house dust mites. is tendency became stronger when asthma or allergy was pres- ent in the mouse families because allergen-specific antibodies were passed from mouse parents to their newborns, thereby increasing that sensitivity further. In mice: Early RSV protection prevented development of asthma Importantly, the researchers dis- covered that when the mouse newborns were protected from RSV, those harmful immune shifts did not occur and asthma development was prevented. Based on their findings, the researchers suggest that protect- ing newborns from RSV could substantially reduce asthma cases later in life. In addition, the results could help encourage RSV vacci- nation, given that it may help boost children's respiratory health in the long-term. RSV vaccines available but use is inconsistent e first RSV vaccines were approved and introduced in 2023, including GSK's Arexvy ® and Pfizer's Abrysvo ® . Current regulatory approvals vary by age group, vaccine and country. As of late 2025, more than 40 coun- tries, primarily in high-income regions, including the US, UK, Canada, Australia and multiple European countries, have rolled out vaccination programs. To protect infants, those pro- grams consist of either maternal vaccination (typically in the third trimester) or long-acting mono- clonal antibodies (nirsevimab) for infants. When women are immunized during pregnancy, the vaccine is designed to gener- ate antibodies that transfer to a developing fetus. e World Health Organiza- tion (WHO) recommends global introduction of both maternal vac- A limitation of the study was the inclusion of asthma and RSV infection diagnosed in hospitals only, "with a risk of missing milder disease forms seen only by general practitioners in community medi- cal care," the researchers explained. "It was initially thought that only severe bronchiolitis requiring hos- pitalization was a risk factor for asthma, but recent, elegant work employing surveillance hRSV detection in cohorts of newborns suggest that milder hRSV infec- tion could also be a risk factor for asthma. erefore, our study likely underestimates the true hRSV- attributable asthma risk." In mice: Early RSV magnified immune response to allergens In the experimental model using mice, the researchers found that infant mice who suffered severe RSV infections in their first months of life were more likely to develop immune responses that pared with uninfected children of nonasthmatic parents. Furthermore, having a parent with allergic rhinitis (AR, i.e., hay fever) was a risk factor for asthma development, with the highest risk among those children both hospi- talized for RSV and born to a par- ent with AR. e risk was higher when the mother was taking an AR medication (HR 4.09) than when the father was taking an AR medication (HR 3.77) and greater still when both parents were tak- ing an AR medication (HR 4.98) than in uninfected children of par- ents without AR. e results showed that "even chil- dren without a parental history of asthma have an increased risk of developing asthma following hRSV [human RSV] hospitaliza- tion," Lambrecht and colleagues noted. "is finding challenges the notion that only genetically predisposed children are hospital- ized for hRSV and later go on to develop asthma." Please add inhalationmag.com to your safe senders list

Articles in this issue

Links on this page

view archives of Inhalation - INH0426